Organoid Sciences
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Organoid Sciences - overview
Established
2018
Location
Seongnam, Gyeonggi, South Korea
Primary Industry
Biotechnology
About
Based in Seongnam, South Korea, and founded in 2018, Organoid Sciences operates as a biotechnology company that develops new drugs for incurable disease by by utilizing organoids, which is a type of stem cell that can reproduce human organs. In 2020, Organoid Sciences was selected for stem cell regeneration medical project by the Ministry of Health and Welfare. The company's current CEO is Jongman Yu. Organoid Sciences engages in the R&D of drug development platform for treating incurable diseases.
Organoid Sciences uses organoid based regeneration technology that can reproduce human organs such as pancreases, liver, etc. The company has also developed technologies for ADIO platform based immune assessment and infectious disease analysis through microbiome therapy.
Current Investors
CHA Biotech Co., Ltd., AJU IB Investment, LB Investment
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.organoidrx.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.